us share market


Both sides of the Brexit negotiation are probing each others’ intentions and capabilities, whilst keeping a close eye upon their own restive and growing populist voters. Their reactions to the growing populist threats come straight from the same page. Prime Minister May has recently rolled out the Conservative Party version of Fabian research, originating in Beatrice and Sidney Webb’s Minority Report, into the conditions of the underprivileged in society and remedial solutions to their plight. The reciprocal European Union (EU) initiative, to be inclusive and to enable social mobility, mirrors that in Britain. This positioning complies with the new G20 agenda and IMF managing director Lagarde’s latest buzzword, “inclusiveness”; so that everything remains in globalist compliance. The resulting political parameters of these two focus points is setting the agenda and driving the Brexit negotiation process.

us share market: AmerisourceBergen Corporation (Holding Co )(ABC)


Advisors’ Opinion:

  • [By Ben Levisohn]

    AmerisourceBergen (ABC) sprinted to the top of the S&P 500 after releasing Street-beating earnings this morning.

    Getty Images

    Shares of AmerisourceBergen jumped 8.8% to $$75.96 today, while the S&P 500 dropped fell 0.7% to 2,097.94.

    Leerink’s David Larsen and Matt Dellelo traces today’s big gain to Amerisource’s big drop following McKesson’s (MCK) earnings last week:


    This morningAmerisourceBergen reported adjusted EPS of $1.30, which was well ahead of Leerink/consensus of $1.22/$1.22. The quality of the beat appears decent, with some pressure in gross margin, completely offset by lower SG&A costs. Given the dramatic reduction in guidance provided byMcKesson (MP), investors had been very cautious heading into the quarter. We are pleased to see that F2017 EPS guidance of $5.63-$5.88 brackets Leerink/consensus estimates of $5.85/$5.82. Brand inflation is now expected to be in the +7-9% range from 10% previously, and F2017 is expected to be back-half loaded. Our first impression of the quarter is that the print and guide are good and there will likely be a relief rally in the shares.


    AmerisourceBergen’s market capitalization rose to $18.1 billion from $16.6 billion yesterday.

us share market: The Rubicon Project, Inc.(RUBI)

Advisors’ Opinion:

  • [By Paul Ausick]

    The Rubicon Project Inc. (NYSE: RUBI) dropped about 2.4% on Tuesday to post a new 52-week low of $8.64 against a 52-week high of $20.37. Volume of around 680,000 million was about 15% below the daily average of around 780,000. The stock closed at $8.85 on Monday night. The ad marketplace has formed a strategic alliance with Flipboard that will allow advertisers to buy ad space on Flipboard.

  • [By Lisa Levin]

    The Rubicon Project Inc (NYSE: RUBI) shares dropped 28 percent to $6.08. Rubicon Project reported upbeat results for its fourth quarter and named Michael Barrett as CEO.

  • [By Paul Ausick]

    Rubicon Project Inc. (NYSE: RUBI) dropped about 1.9% Friday, to post a new 52-week low of $5.65 after closing at $5.76 on Thursday. The stock’s 52-week high is $20.37. Volume was nearly 4 times the daily average of around 740,000 shares. The company had no specific news.

  • [By Paul Ausick]

    Rubicon Project Inc. (NYSE: RUBI) dropped about 29% Wednesday to post a new 52-week low of $5.96 after closing Tuesday at $8.39. Volume of more than 6.1 million shares was more than 10 times the daily average of less than 600,000. The company named a new CEO and reported weak results after markets closed Tuesday.

us share market: Cerulean Pharma Inc.(CERU)

Advisors’ Opinion:

  • [By Lisa Levin]

    Cerulean Pharma Inc (NASDAQ: CERU) shares dropped 62 percent to $1.27. Cerulean Pharma and Dar茅 Bioscience reported that they have entered into a stock purchase agreement. Cerulean also announced plans to reduce workforce by 11 people. The company reported that it has sold CRLX101 and CRLX301 to BlueLink Pharmaceuticals for $1.5 million and also agreed to sell Dynamic Tumor Targeting Platform to Novartis for $6 million.

  • [By Lisa Levin] Related CRMD Mid-Day Market Update: U.S. Stocks Turn Negative; AveXis Shares Spike Higher 12 Biggest Mid-Day Gainers For Tuesday CorMedix's (CRMD) CEO Khoso Baluch on Q4 2016 Results – Earnings Call Transcript (Seeking Alpha) Related BIOA Mid-Day Market Update: U.S. Stocks Turn Negative; AveXis Shares Spike Higher Mid-Morning Market Update: Markets Edge Higher; Tiffany Earnings Top Estimates BioAmber (BIOA) Q4 2016 Results – Earnings Call Transcript (Seeking Alpha) CorMedix Inc. (NYSE: CRMD) shares fell 27.5 percent to $1.50 after the company reported Q4 results and issued a business update. Bioamber Inc (NYSE: BIOA) shares tumbled 23.6 percent to $2.40. BioAmber reported FY16 adjusted loss of $1.07 per share on revenue of $8.3 million. The Medicines Company (NASDAQ: MDCO) shares dipped 20.9 percent to $41.62. Innocoll Holdings PLC (NASDAQ: INNL) shares fell 20.3 percent to $1.49. Innocoll posted a narrower-than-expected quarter loss, but revenue missed estimates. Stifel Nicolaus downgraded Innocoll from Buy to Hold. Rosetta Genomics Ltd. (USA) (NASDAQ: ROSG) shares declined 20.3 percent to $3.83. On Thursday, Rosetta Genomics disclosed a 1-for-12 reverse stock split. Esperion Therapeutics Inc (NASDAQ: ESPR) shares dropped 19.9 percent to $23.76. Esperion Therapeutics shares have jumped 106.19 percent over the past 52 weeks, while the S&P 500 index has gained 16.70 percent in the same period. AmTrust Financial Services Inc (NASDAQ: AFSI) tumbled 18.3 percent to $17.65. AmTrust Financial disclosed that it will delay its annual report filing for the fiscal year ended December 31, 2016. Qualstar Corporation (NASDAQ: QBAK) slipped 17.7 percent to $6.85. Qualstar reported a Q4 loss of $0.20 per share on revenue of $2.2 milli
  • [By Lisa Levin] Related Mid-Afternoon Market Update: CytomX Therapeutics Climbs Following Bristol-Myers Squibb Partnership; Medgenics Shares Slide 15 Biggest Mid-Day Losers For Monday Cerulean Pharma's (CERU) CEO Chris Guiffre on Cerulean and Dar茅 Proposed Transaction (Transcript) (Seeking Alpha) Related Mid-Afternoon Market Update: Cancer Genetics Gains After Q4 Results; Heat Biologics Shares Slide Mid-Day Market Update: Dow Rises Over 50 Points; Tandem Diabetes Care Shares Plunge Tandem Diabetes prices stock offering at $1.25; shares off 19% premarket (Seeking Alpha) Cerulean Pharma Inc (NASDAQ: CERU) shares dipped 27 percent to $0.817. Cerulean Pharma shares have dropped 60.28 percent over the past 52 weeks, while the S&P 500 index has gained 15.31 percent in the same period. Tandem Diabetes Care Inc (NASDAQ: TNDM) shares tumbled 24.2 percent to $1.17. Tandem Diabetes Care priced 18 million share offering at $1.25 per share. Alphatec Holdings Inc (NASDAQ: ATEC) shares fell 21.1 percent to $2.10 as the company reported a $18.9 million private placement. Heat Biologics Inc (NASDAQ: HTBX) shares dropped 15.5 percent to $0.870. Heat Biologics priced its 5 million share offering at $0.80 per share. Rave Restaurant Group Inc (NASDAQ: RAVE) shares fell 15 percent to $1.76. QuickLogic Corporation (NASDAQ: QUIK) shares declined 12.2 percent to $1.58. QuickLogic priced its 10 million share offering at $1.50 per share. Orion Engineered Carbons SA (NYSE: OEC) shares dropped 9.5 percent to $19.10. Orion Engineered Carbons reported a 5 million common stock secondary offering. Interpace Diagnostics Group Inc (NASDAQ: IDXG) shares fell 8.7 percent to $2.61 after the company reported debt restructuring and agreed to eliminate its royalty and mileston

us share market: Extra Space Storage Inc(EXR)


Advisors’ Opinion:

  • [By Matthew Frankel]

    The final REIT type I like right now is self-storage, particularly Extra Space Storage (NYSE:EXR).

    First, I should mention that this could prove to be the most volatile company on the list. Self-storage isn’t as defensive as retail or healthcare simply because of its lease structure. Generally, you don’t sign a multi-year lease on a storage unit — you just pay each month that you want to keep it. This makes it easier for tenants to vacate the properties during tough times.

us share market: BioAmber Inc.(BIOA)


Advisors’ Opinion:

  • [By Markus Aarnio]

    BioAmber (BIOA) is a sustainable chemicals company. Its proprietary technology platform combines industrial biotechnology and chemical catalysis to convert renewable feedstock into chemicals for use in a wide variety of everyday products including plastics, resins, food additives and personal care products.

  • [By Lisa Levin] Related CRMD Mid-Day Market Update: U.S. Stocks Turn Negative; AveXis Shares Spike Higher 12 Biggest Mid-Day Gainers For Tuesday CorMedix's (CRMD) CEO Khoso Baluch on Q4 2016 Results – Earnings Call Transcript (Seeking Alpha) Related BIOA Mid-Day Market Update: U.S. Stocks Turn Negative; AveXis Shares Spike Higher Mid-Morning Market Update: Markets Edge Higher; Tiffany Earnings Top Estimates BioAmber (BIOA) Q4 2016 Results – Earnings Call Transcript (Seeking Alpha) CorMedix Inc. (NYSE: CRMD) shares fell 27.5 percent to $1.50 after the company reported Q4 results and issued a business update. Bioamber Inc (NYSE: BIOA) shares tumbled 23.6 percent to $2.40. BioAmber reported FY16 adjusted loss of $1.07 per share on revenue of $8.3 million. The Medicines Company (NASDAQ: MDCO) shares dipped 20.9 percent to $41.62. Innocoll Holdings PLC (NASDAQ: INNL) shares fell 20.3 percent to $1.49. Innocoll posted a narrower-than-expected quarter loss, but revenue missed estimates. Stifel Nicolaus downgraded Innocoll from Buy to Hold. Rosetta Genomics Ltd. (USA) (NASDAQ: ROSG) shares declined 20.3 percent to $3.83. On Thursday, Rosetta Genomics disclosed a 1-for-12 reverse stock split. Esperion Therapeutics Inc (NASDAQ: ESPR) shares dropped 19.9 percent to $23.76. Esperion Therapeutics shares have jumped 106.19 percent over the past 52 weeks, while the S&P 500 index has gained 16.70 percent in the same period. AmTrust Financial Services Inc (NASDAQ: AFSI) tumbled 18.3 percent to $17.65. AmTrust Financial disclosed that it will delay its annual report filing for the fiscal year ended December 31, 2016. Qualstar Corporation (NASDAQ: QBAK) slipped 17.7 percent to $6.85. Qualstar reported a Q4 loss of $0.20 per share on revenue of $2.2 milli
  • [By Lisa Levin]

    Bioamber Inc (NYSE: BIOA) shares dropped 19 percent to $2.55. BioAmber reported FY16 adjusted loss of $1.07 per share on revenue of $8.3 million.

  • [By Maxx Chatsko]

    While companies with lower-priced shares are often riskier than those with higher prices, some companies trading under $5 per share have intriguing potential. Investors searching for overlooked growth opportunities should consider industrial biotech BioAmber (NYSE:BIOA), pharmaceutical services company Codexis (NASDAQ:CDXS), and one-trick-pony biopharma Keryx Biopharmaceuticals (NASDAQ:KERX).

  • [By Paul Ausick]

    BioAmber Inc. (NYSE: BIOA) dropped nearly 29% Friday to post a new 52-week low of $2.24 after closing Thursday at $3.14. Volume of more than 1.5 million shares was about 6 times the daily average of around 240,000. The company’s annual report, filed on Thursday with its quarterly results, included a “going concern” statement from the company’s independent auditing firm.

Leave a Reply

Your email address will not be published. Required fields are marked *